Covered recipient · General Payments record
KIMBERLY ANNE PETRUSO
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$1,199.24
- Reported across 64 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $353.60 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $146.07 | 7 |
| Lilly USA, LLC | $93.09 | 5 |
| Abbott Laboratories | $71.98 | 4 |
| Acerta Pharma LLC | $25.47 | 1 |
| ABBVIE INC. | $16.99 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $17.10 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124809849 | CMS |
| Abbott Laboratories | $18.02 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124809851 | CMS |
| Abbott Laboratories | $17.63 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124809853 | CMS |
| Abbott Laboratories | $19.23 | 09/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124809855 | CMS |
| ABBVIE INC. | $16.99 | 11/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105252999 | CMS |
| AstraZeneca Pharmaceuticals LP | $25.47 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104202093 | CMS |
| Lilly USA, LLC | $19.14 | 02/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135107567 | CMS |
| Lilly USA, LLC | $19.14 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135133432 | CMS |
| Lilly USA, LLC | $20.14 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135133436 | CMS |
| Lilly USA, LLC | $17.02 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135112572 | CMS |
| Lilly USA, LLC | $17.65 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135133434 | CMS |
| Novo Nordisk Inc | $19.08 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096834589 | CMS |
| Novo Nordisk Inc | $19.62 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097232573 | CMS |
| Novo Nordisk Inc | $18.48 | 03/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097507211 | CMS |
| Novo Nordisk Inc | $19.36 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097743063 | CMS |
| Novo Nordisk Inc | $23.69 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096642061 | CMS |
| Novo Nordisk Inc | $22.73 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097776656 | CMS |
| Novo Nordisk Inc | $23.11 | 10/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097239995 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.